BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 11423988)

  • 1. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
    Bessa M; Saville MK; Watson RJ
    Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties.
    Saville MK; Watson RJ
    Oncogene; 1998 Nov; 17(21):2679-89. PubMed ID: 9840932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain.
    Petrovas C; Jeay S; Lewis RE; Sonenshein GE
    Oncogene; 2003 Apr; 22(13):2011-20. PubMed ID: 12673206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators.
    Morris L; Allen KE; La Thangue NB
    Nat Cell Biol; 2000 Apr; 2(4):232-9. PubMed ID: 10783242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107.
    Joaquin M; Bessa M; Saville MK; Watson RJ
    Oncogene; 2002 Nov; 21(52):7923-32. PubMed ID: 12439743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites.
    Santilli G; Cervellera MN; Johnson TK; Lewis RE; Iacobelli S; Sala A
    Oncogene; 2001 Dec; 20(57):8167-74. PubMed ID: 11781832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation.
    Lane S; Farlie P; Watson R
    Oncogene; 1997 May; 14(20):2445-53. PubMed ID: 9188859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites.
    Bartusel T; Schubert S; Klempnauer KH
    Gene; 2005 May; 351():171-80. PubMed ID: 15922873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An alternatively spliced isoform of B-Myb is a transcriptional inhibitor.
    Horstmann S; Ferrari S; Klempnauer KH
    Oncogene; 2000 Nov; 19(48):5428-34. PubMed ID: 11114719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M.
    Oelgeschläger M; Janknecht R; Krieg J; Schreek S; Lüscher B
    EMBO J; 1996 Jun; 15(11):2771-80. PubMed ID: 8654374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
    Joaquin M; Watson RJ
    J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
    Luciani MG; Hutchins JR; Zheleva D; Hupp TR
    J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-cycle regulation of B-Myb protein expression: specific phosphorylation during the S phase of the cell cycle.
    Robinson C; Light Y; Groves R; Mann D; Marias R; Watson R
    Oncogene; 1996 May; 12(9):1855-64. PubMed ID: 8649845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redundant functions of B-Myb and c-Myb in differentiating myeloid cells.
    Golay J; Broccoli V; Borleri GM; Erba E; Faretta M; Basilico L; Ying GG; Piccinini G; Shapiro LH; Lovrić J; Nawrath M; Mölling K; Rambaldi A; Introna M
    Cell Growth Differ; 1997 Dec; 8(12):1305-16. PubMed ID: 9419419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linking Myb to the cell cycle: cyclin-dependent phosphorylation and regulation of A-Myb activity.
    Ziebold U; Klempnauer KH
    Oncogene; 1997 Aug; 15(9):1011-9. PubMed ID: 9285555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter.
    Kamano H; Klempnauer KH
    Oncogene; 1997 Mar; 14(10):1223-9. PubMed ID: 9121772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cyclin A/Cdk2 phosphorylation sites in B-Myb.
    Bartsch O; Horstmann S; Toprak K; Klempnauer KH; Ferrari S
    Eur J Biochem; 1999 Mar; 260(2):384-91. PubMed ID: 10095772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
    Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
    Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of beta3-endonexin mutants for their ability to interact with cyclin A.
    Ohtoshi A; Otoshi H
    Mol Genet Genomics; 2001 Dec; 266(4):664-71. PubMed ID: 11810239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation.
    De Falco G; Bagella L; Claudio PP; De Luca A; Fu Y; Calabretta B; Sala A; Giordano A
    Oncogene; 2000 Jan; 19(3):373-9. PubMed ID: 10656684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.